Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule. Why is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patients. Radiotherapy helps control this, but the best way to deliver it-especially the number of sessions and whether to treat the pelvic area-is still being studied. Shorter treatments could mean less time in therapy and better quality of life, if such treatments are proven safe. What is being compared? Standard treatment (Arm A): 25 sessions (about 5 weeks) Prostate bed: 62.5 Gy Pelvis: 45 Gy Shorter treatment (Arm B): 20 sessions (about 4 weeks) Prostate bed: 52.5 Gy Pelvis: 43 Gy Both groups may also receive hormone therapy (ADT) for 6-24 months. Main Goal To check if the shorter treatment causes no more side effects (urinary or bowel problems) than the standard treatment, while keeping cancer control similar. Other Things to be Measured Cancer control (PSA levels, spread of disease) Survival Quality of life (urinary, bowel, sexual health questionnaires) Who can join? Men who: Had prostate surgery Have a detectable PSA (≥0.2 ng/mL) No distant metastasis Are in good general health (ECOG 0-2) How long will the study last? About 12 years total: 2 years to enroll patients 10 years of follow-up
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak prostaty.
- •Przeszczepili prostatę i mają podwyższony poziom PSA (≥0.2 ng/mL).
- •Nie mają przerzutów do innych narządów.
- •Mają nawrót raka w obrębie miednicy.
- •Są w dobrym ogólnym stanie zdrowia.
- •Mają ukończone 18 lat.
- •Mają prawidłowe funkcje nerek, wątroby i krwi.
✗ Disqualifies
- •Nie byli wcześniej leczeni radioterapią w okolicy miednicy.
- •Mają widoczny nawrót raka na obrazach badań.
- •Mają rozsiane przerzuty choroby.
- •Mają aktywne choroby zapalne jelit lub inne problemy trawienne, które mogą pogorszyć się po radioterapii.
- •Mają inne poważne choroby utrudniające udział w badaniu.
- •Byli wcześniej leczeni systemowo na nawrót raka prostaty (z wyjątkiem terapii hormonalnej podanej mniej niż 6 miesięcy temu).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (4)
Gatineau Hospital
Gatineau, Canada
Hôpital Général Juif
Montreal, Canada
McGill University Health Centre
Montreal, Canada
CHU de Québec-Université Laval
Québec, Canada
Trial contact
Eric Vigneault, MD, MSc
Damien Carignan, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.